Literature DB >> 19549578

Neutropenic fever syndromes in patients undergoing cytotoxic therapy for acute leukemia and myelodysplastic syndromes.

E J Bow1.   

Abstract

Fever represents the major surrogate of infection in neutropenic cancer patients. A number of neutropenic fever syndromes have been recognized, the causes and significance of which will vary depending upon the clinical context. First neutropenic fever syndromes are typically of bacterial origin, the character of which may be influenced by whether antibacterial chemoprophylaxis has been administered. Persistent neutropenic fevers are documented during the empirical systemic antibacterial therapy for the first neutropenic fever, the cause of which is likely outside the spectrum of activity of the initial therapy. Recrudescent neutropenic fevers, defined by the appearance of a new fever after defervescence of the first fever, are often a function of invasive fungal infection or gram-positive infections outside the spectrum of the initial empirical antibacterial regimen. The myeloid reconstitution syndrome occurs in parallel with neutrophil recovery from aplasia and may not necessarily represent new infection. Recognition of these patterns can help the clinician make better clinical judgments and management plans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19549578     DOI: 10.1053/j.seminhematol.2009.03.002

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  13 in total

Review 1.  Febrile neutropenia in hematologic malignancies.

Authors:  Michael K Keng; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

2.  Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.

Authors:  George Dranitsaris; Haytham Khoury
Journal:  Support Care Cancer       Date:  2010-10-23       Impact factor: 3.603

3.  Sepsis in the severely immunocompromised patient.

Authors:  Andre C Kalil; Steven M Opal
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

4.  Synthesis and antifungal activity of functionalized 2,3-spirostane isomers.

Authors:  Sunil Kumar Upadhyay; Clinton C Creech; Katharine L Bowdy; Edwin D Stevens; Branko S Jursic; Donna M Neumann
Journal:  Bioorg Med Chem Lett       Date:  2011-03-30       Impact factor: 2.823

5.  Antibiotic therapy in hematological neutropenic patients: what is the news?

Authors:  F Pea
Journal:  Leuk Suppl       Date:  2012-08-09

6.  Rhizopus arrhizus and Fusarium solani Concomitant Infection in an Immunocompromised Host.

Authors:  João N de Almeida Júnior; Karim Y Ibrahim; Gilda M B Del Negro; Evandro D Bezerra; Amaro N Duarte Neto; Marjorie V Batista; Rinaldo F Siciliano; Mauro C Giudice; Adriana L Motta; Flávia Rossi; Ligia C Pierrotti; Maristela P Freire; Marcelo Bellesso; Juliana Pereira; Edson Abdala; Gil Benard
Journal:  Mycopathologia       Date:  2015-09-07       Impact factor: 2.574

7.  Obesity in pediatric patients with acute lymphoblastic leukemia increases the risk of adverse events during pre-maintenance chemotherapy.

Authors:  Chelsea K Meenan; John A Kelly; Li Wang; A Kim Ritchey; Scott H Maurer
Journal:  Pediatr Blood Cancer       Date:  2018-10-26       Impact factor: 3.167

8.  Inducible epithelial resistance protects mice against leukemia-associated pneumonia.

Authors:  Miguel M Leiva-Juárez; Hayden H Ware; Vikram V Kulkarni; Patrick A Zweidler-McKay; Michael J Tuvim; Scott E Evans
Journal:  Blood       Date:  2016-06-17       Impact factor: 22.113

9.  Invasive fungal infection of the central nervous system in a patient with acute myeloid leukaemia.

Authors:  Anna Janik-Moszant; Aleksander Matyl; Iwona Rurańska; Agnieszka Machowska-Majchrzak; Ewa Kluczewska; Tomasz Szczepański
Journal:  Pol J Radiol       Date:  2012-01

10.  Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.

Authors:  Pudjo H Widjajanto; Sumadiono Sumadiono; Jacqueline Cloos; Ignatius Purwanto; Sutaryo Sutaryo; Anjo Jp Veerman
Journal:  J Blood Med       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.